Salt and crystal form of egfr inhibitor, and composition and use thereof
US-2024352053-A1 · Oct 24, 2024 · US
Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase
US9593136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593136-B2 |
| Application number | US-201214130384-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2012 |
| Priority date | Jul 1, 2011 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the chemical structure of formula (II) wherein X is 1) a carboxylate, phosphonate, sulfate, an ester thereof, or a salt thereof, or 2) a tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, wherein “n is 1” and are not simultaneously satisfied. 2. The compound of claim 1 , wherein Ar is a phenyl or a heteroaromatic group. 3. A compound having the chemical structure of formula (II) wherein X is 1) a carboxylate, phosphonate, sulfate, an ester thereof, or a salt thereof, or 2) a tetrazol; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and wherein n is 2, 3, or 4. 4. A compound having the chemical structure of formula (II) wherein X is a phosphonate, an ester thereof, or a salt thereof; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, wherein “n is 1” and are not simultaneously satisfied. 5. The compound of claim 1 , selected from the group consisting of: 6. A pharmaceutical composition comprising a compound having the chemical structure of formula (II) wherein X is 1) a carboxylate, phosphonate, sulfate, an ester thereof, or a salt thereof, or 2) tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, wherein “n is 1” and are not simultaneously satisfied. 7. The composition of claim 6 , wherein Ar is a phenyl or a heteroaromatic group. 8. A pharmaceutical composition comprising a compound having the chemical structure of formula (II) where X is 1) a carboxylate, phosphonate, sulfate, an ester thereof, or a salt thereof, or 2) a tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; wherein n is 2, 3, or 4. 9. A pharmaceutical composition comprising the compound of claim 5 .
Assignees
Inventors
Classifications
- A61K31/66Primary
Phosphorus compounds · CPC title
N-acyl derivatives · CPC title
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
- C07F9/4021Primary
Esters of aromatic acids (P-C aromatic linkage) · CPC title
involving isomerase · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9593136B2 cover?
- In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a subs…
- Who is the assignee on this patent?
- Boshoff Helena I, Dowd Cynthia S, Jackson Emily R, and 8 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/66. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).